Lixte Biotechnology Holdings Inc(LIXT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.12 | Insider Own | 12.02% | Shs Outstand | 17.4M | Perf Week | 8.42% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 15.3M | Perf Month | 2.41% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | - | Inst Own | 4.21% | Short Float | 2.52% | Perf Quarter | 135.24% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -21.49% | Short Ratio | 1.71 | Perf Half Y | 84.87% |
| Sales | 0.00B | P/B | 10.56 | EPS next 5Y | - | ROA | -116.7% | Short Interest | 0.39M | Perf YTD | 83.46% |
| Book/sh | 0.68 | P/C | 38.57 | EPS past 3/5Y | 31.98% 15.39% | ROE | -158.69% | 52W High | -13.93% ($8.38) | Perf Year | 256.93% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -85.93% | 52W Low | 463.28% ($1.28) | Perf 3Y | 22.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 22.5% | Gross Margin | - | Volatility(W/M) | 13% 12.19% | Perf 5Y | -77.47% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.82 | Perf 10Y | -51.93% |
| Dividend Ex-Date | - | Quick Ratio | 2.78 | EPS Q/Q | 37.9% | Profit Margin | - | RSI (14) | 54.44 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.78 | Sales Q/Q | - | SMA20 | 1.66% ($7.09) | Beta | 1.26 | Target Price | - |
| Payout | - | Debt/Eq | 0.13 | Earnings | - | SMA50 | 23.69% ($5.83) | Rel Volume | 2.72 | Prev Close | $7.67 |
| Employees | 3 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | - | SMA200 | 67.25% ($4.31) | Avg Volume(3M) | 0.23M | Price | $7.21 |
| IPO | 2007/9/21 | Option/Short | No/Yes | Trades | 3776 | Volume | 613,903 | Change | -6% |
🔬 Linnaeus Biosciences (LIXT) is a US-based clinical-stage oncology drug developer focused on novel cancer therapies. Centered on its lead candidate LBT-100, which inhibits protein phosphatase 2A (PP2A), the company pursues a precision oncology strategy that disrupts tumor cell DNA repair mechanisms and enhances immune response. Through collaborations with major cancer centers and large pharmaceutical companies, Linnaeus Biosciences is expanding its clinical pipeline.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded more than usual. That is 272% of its average volume.
LIXT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.5%. The S&P 500 did +61% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #339 of 599 in the industry
Based on market cap of $125M.
FAQ
What kind of company is LIXT?
LIXT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LIXT?
The market cap of LIXT is approximately $125M, ranking 4,460 within its sector.
What is the 52-week high and low for LIXT?
LIXT has recorded a 52-week high of $8.38 and a low of $1.28.